viewSummit Therapeutics PLC

Summit Therapeutics' study identifies DMD biomarkers

Summit is developing for a treatment for DMD using utrophin modulator therapies

DMD is caused by the absence of dystrophin protein

Summit Therapeutics plc (NASDAQ: SMMT LON:SUMM) has identified biomarkers to relate muscle regeneration and the presence of utrophin protein in patients with Duchenne (DMD) and Becker muscular dystrophy (BMD).

DMD is caused by the absence of dystrophin protein and it is believed utrophin modulation, a naturally occurring protein similar to dystrophin, could slow or even stop the progression of DMD.

Summit is developing for a treatment for DMD using utrophin modulator therapies and sponsored the study at the Institute of Child Health at UCL alongside children’s charity Joining Jack 

“Our data show it is possible to reproducibly measure utrophin protein and distinguish between repairing and mature muscle fibres at the single fibre level in DMD and BMD muscle biopsies,”  said Jenny Morgan, Professor in Cell Biology at the ICH.

“This has led to important observations correlating regeneration and disease severity and so these biomarkers have application in clinical trials to potentially monitor activity of utrophin modulator therapies such as Summit's SMT C1100," she added.

Summit has just started a phase II proof of concept study for its SMT C1100 treatment.

Quick facts: Summit Therapeutics PLC

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...



Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 02/10/2020

2 min read